Pathways and mechanisms of venetoclax resistance
نویسندگان
چکیده
منابع مشابه
HIV entry inhibitors: mechanisms of action and resistance pathways.
Entry inhibitors represent a new generation of antivirals for the treatment of HIV infection. Several compounds which block the attachment of HIV gp120 to either the CD4 T cell receptor or the CCR5/CXCR4 co-receptors are currently in clinical development. Most of these compounds have different molecular structures and specific mechanisms of action. These agents are eagerly awaited by a growing ...
متن کاملAntifungal drug resistance of yeasts in dermatology: mechanisms, epidemiology and clinical impact
Superficial dermatophytoses are among the most common infectious disease. The most commonly used antifungal categories reazoles, polyenes and echinocandins. Due to the limited number of available antifungal drugs, toxicity and the emergence of resistant (intrinsic or acquired) strains, antifungal strategy needs to be developed. Recently the researchers try to find alternative antifungal agents....
متن کاملDNA Repair Pathways and Mechanisms
Our cells are constantly exposed to insults from endogenous and exogenous agents that can introduce damage into our DNA and generate genomic instability. Many of these lesions cause structural damage to DNA and can alter or eliminate fundamental cellular processes, such as DNA replication or transcription. DNA lesions commonly include base and sugar modifications, singleand double-strand breaks...
متن کاملMechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of breast tumors express the estrogen receptor (ER). Tamoxifen and aromatase inhibitors (AIs) are the most common and effective therapies for patients with ERα-positive breast cancer. Alone or combined with chemotherapy, tamoxifen significantly reduces disease progression and is associated with more favorable im...
متن کاملVenetoclax and obinutuzumab in chronic lymphocytic leukemia.
Kirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, Mark Dixon, Jasmin Bahlo, Simon Warburton, Thomas J. Kipps, Robert Weinkove, Sue Robinson, Till Seiler, Stephen Opat, Carolyn Owen, Javier López, Kathryn Humphrey, Rod Humerickhouse, Eugen Tausch, Lukas Frenzel, Barbara Eichhorst, Clemens-M. Wendtner, Stephan Stilgenbauer, Anton W. Langerak, Jacque J.M. van Dongen, Sebastian Boettcher, Matthias...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia & Lymphoma
سال: 2017
ISSN: 1042-8194,1029-2403
DOI: 10.1080/10428194.2017.1283032